Federal Register / Vol. 88, No. 186 / Wednesday, September 27, 2023 / Notices 66451 

information about the Committee, 

including meeting materials and 

agendas, will be made available on-line 

at https://www.gsa.gov/gbac. 

SUPPLEMENTARY INFORMATION: 

Procedures for Attendance and Public 

Comment 

To register to attend the November 

2nd meeting as a public observer, please 

send the following information via 

email to gbac@gsa.gov: your first and 

last name, organization and email 

address and whether you would like to 

provide public comment. Requests to 

observe the November 2nd, 2023 

meeting must be received by 12 p.m. ET, 

on Monday, October 30, 2023 to receive 

the meeting information. 

Requests to observe the full series of 

Task Group meetings must be received 

by 5 p.m. ET on the Monday before the 

meeting in question. Since Task Group 

meetings are conducted as a series, it 

will be most useful to observe all or 

most of them from the start. 

For all online meetings, Web meeting 

attendance information will be provided 

following registration. Time will be 

provided at all meetings for public 

comment wherever possible. 

GSA will be unable to provide 

technical assistance to any listener 

experiencing technical difficulties. 

Testing access to the Web meeting site 

before the calls is recommended. To 

request an accommodation, such as 

closed captioning, or to ask about 

accessibility, please contact Mr. Bloom 

at gbac@gsa.gov at least five business 

days prior to the meeting to give GSA 

as much time as possible to process the 

request. 

Background 

The Administrator of GSA established 

the Committee on June 20, 2011 

(Federal Register/Vol. 76, No. 118) 

pursuant to Section 494 of the Energy 

Independence and Security Act of 2007 

(EISA, 42 U.S.C. 17123). Under this 

authority, the Committee provides 

independent policy advice and 

recommendations to GSA to advance 

federal building innovations in 

planning, design, and operations to 

reduce costs, enable agency missions, 

enhance human health and 

performance, and minimize 

environmental impacts. 

November 2nd Meeting Agenda 

• Welcome 

• Introductions 

• Task Group Presentations, 

Recommendations and Vote (as 

needed) 

Æ Federal Building Decarbonization 

Æ Green Leasing 

• Working Lunch with Speaker 

• Discussion of Next Potential 

Committee Topics 

• Public Comments 

• Adjourn 

Green Building Advisory Committee 

Federal Building Decarbonization Task 

Group 

The Federal Building Decarbonization 

Task Group will work to develop 

recommendations to the full Committee 

to propose to GSA, to prioritize federal 

building decarbonization strategies. 

This phase of the Task Group builds on 

the findings of the first two phases of 

this Task Group with a deeper 

investigation of issues related to 

beneficial federal building 

electrification. 

Kevin Kampschroer, 

Federal Director, Office of Federal HighPerformance Green Buildings, General 

Services Administration. 

[FR Doc. 2023–20967 Filed 9–26–23; 8:45 am] 

BILLING CODE 6820–14–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2023–0079] 

Advisory Committee on Immunization 

Practices 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice and request for comment. 

SUMMARY: In accordance with regulatory 

provisions, the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

Advisory Committee on Immunization 

Practices (ACIP). This meeting is open 

to the public. Time will be available for 

public comment. 

DATES: The meeting will be held on 

October 25, 2023, from 8 a.m. to 5 p.m., 

EDT, October 26, 2023, from 8 a.m. to 

5 p.m., EDT, and October 27, 2023, from 

8 a.m. to 12 p.m., EDT (times subject to 

change; see the ACIP website for 

updates: https://www.cdc.gov/vaccines/ 

acip/index.html). 

Written comments must be received 

between October 2–13, 2023. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2023– 

0079, by either of the methods listed 

below. CDC does not accept comments 

by email. 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Ms. Stephanie Thomas, ACIP 

Meeting, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

Mailstop H24–8, Atlanta, Georgia 

30329–4027. Attn: Docket No. CDC– 

2023–0079. 

Instructions: All submissions received 

must include the Agency name and 

docket number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

The meeting will be webcast live via 

the World Wide Web. The webcast link 

can be found on the ACIP website at 

https://www.cdc.gov/vaccines/acip/ 

index.html. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, Committee 

Management Specialist, Advisory 

Committee on Immunization Practices, 

National Center for Immunization and 

Respiratory Diseases, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop H24–8, 

Atlanta, Georgia 30329–4027. 

Telephone: (404) 639–8836; Email: 

ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: Purpose: 

The Advisory Committee on 

Immunization Practices (ACIP) is 

charged with advising the Director, 

Centers for Disease Control and 

Prevention (CDC), on the use of 

immunizing agents. In addition, under 

42 U.S.C. 1396s, the Committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children program, along 

with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under applicable provisions of the 

Affordable Care Act and section 2713 of 

the Public Health Service Act, 

immunization recommendations of 

ACIP that have been approved by the 

Director, CDC, and appear on CDC 

immunization schedules generally must 

be covered by applicable health plans. 

Matters To Be Considered: The agenda 

will include discussions on child and 

adolescent immunization schedules, 

adult immunization schedule, influenza 

vaccines, chikungunya vaccine, COVID– 

19 vaccines, meningococcal vaccines, 

mpox vaccine, pneumococcal vaccines, 

polio vaccines, and respiratory syncytial 


ddrumheller on DSK120RN23PROD with NOTICES1
66452 Federal Register / Vol. 88, No. 186 / Wednesday, September 27, 2023 / Notices 

virus vaccines for older adults. 

Recommendation votes on child and 

adolescent immunization schedules, 

adult immunization schedule, 

meningococcal vaccines, and mpox 

vaccine are scheduled. A Vaccines for 

Children vote on meningococcal 

vaccines and mpox vaccine is 

scheduled. Agenda items are subject to 

change as priorities dictate. For more 

information on the meeting agenda, visit 

https://www.cdc.gov/vaccines/acip/ 

meetings/index.html. 

Meeting Information: The meeting 

will be webcast live via the World Wide 

Web. For more information on ACIP, 

please visit the ACIP website: https://

www.cdc.gov/vaccines/acip/index.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near-duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: The docket 

will be opened to receive written 

comments on October 2, 2023. Written 

comments must be received by October 

13, 2023. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. Oral 

public comment will occur before any 

scheduled votes, including all votes 

relevant to the ACIP’s Affordable Care 

Act and Vaccines for Children Program 

roles. Priority will be given to 

individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the October 25–27, 

2023, ACIP meeting must submit a 

request at https://www.cdc.gov/ 

vaccines/acip/meetings/index.html 

between October 2, 2023, and no later 

than 11:59 p.m., EDT, October 13, 2023, 

according to the instructions provided. 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

time, CDC will conduct a lottery to 

determine the speakers for the 

scheduled public comment session. 

CDC staff will notify individuals 

regarding their request to speak by email 

by October 17, 2023. To accommodate 

the significant interest in participation 

in the oral public comment session of 

ACIP meetings, each speaker will be 

limited to three minutes, and each 

speaker may speak only once per 

meeting. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–20949 Filed 9–26–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–2540–23 and 

CMS–10448] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information (including each proposed 

extension or reinstatement of an existing 

collection of information) and to allow 

60 days for public comment on the 

proposed action. Interested persons are 

invited to send comments regarding our 

burden estimates or any other aspect of 

this collection of information, including 

the necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions, 

the accuracy of the estimated burden, 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected, and the use of automated 

collection techniques or other forms of 

information technology to minimize the 

information collection burden. 

DATES: Comments must be received by 

November 27, 2023. 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number. To be assured 

consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

Submission’’ or ‘‘More Search Options’’ 

to find the information collection 

document(s) that are accepting 

comments. 

2. By regular mail. You may mail 

written comments to the following 

address: CMS, Office of Strategic 

Operations and Regulatory Affairs, 

Division of Regulations Development, 

Attention: Document Identifier/OMB 

Control Number: ll, Room C4–26–05, 

7500 Security Boulevard, Baltimore, 

Maryland 21244–1850. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, please access the CMS PRA 

website by copying and pasting the 

following web address into your web 

browser: https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/

PaperworkReductionActof1995/PRAListing. 

FOR FURTHER INFORMATION CONTACT: 

William N. Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: 

Contents 

This notice sets out a summary of the 

use and burden associated with the 

following information collections. More 

detailed information can be found in 

each collection’s supporting statement 

and associated materials (see 

ADDRESSES). 

CMS–2540–23—Skilled Nursing Facility 

and Skilled Nursing Facility 

Healthcare Complex Report 

CMS–10448—Essential Health Benefits 

Benchmark Plans 

Under the PRA (44 U.S.C. 3501– 

3520), federal agencies must obtain 


ddrumheller on DSK120RN23PROD with NOTICES1